Although ESMO guidelines for CRLM management recommendations have changed over the last 10 years as the understanding of genetics has developed [28,29,30], ESMO’s and other national societies’ [31] recommendations support patients with a CRC metastatic disease KRAS assessment. Here, KRAS is linked to colorectal carcinoma.